Company intelligence / Profile preview

ProZema

Montreal, Quebec, Canada

Ownership: Private
Development stage: Other

Overview

ProZema is a consumer health and biotechnology brand focused on managing skin conditions through the gut-skin axis. The company's flagship product is a clinically proven probiotic supplement designed specifically for individuals with atopic dermatitis and eczema. By utilizing a unique blend of probiotic strains, ProZema aims to reduce the severity of skin inflammation and improve the quality of life for patients. The product is marketed as a natural, evidence-based approach to dermatological health, bridging the gap between nutrition and clinical skincare.

Therapeutic areas: Dermatology
Modalities: Live biotherapeutic product therapyMicrobial therapy
Industry: Food & Nutrition

Beyond the preview

Go deeper on ProZema.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProZema.

Explore the full profile